ClinConnect ClinConnect Logo
Search / Trial NCT03443505

NRD to Predict COPD Exacerbations at Home

Launched by GUY'S AND ST THOMAS' NHS FOUNDATION TRUST · Feb 16, 2018

Trial Information

Current as of April 29, 2025

Completed

Keywords

Chronic Obstructive Pulmonary Disease Acute Exacerbation Neural Respiratory Drive Parasternal Electromyography Respiratory Physiology Lung Function

ClinConnect Summary

Introduction

COPD is a common and serious disease, and is a major burden on patients and the National Health Service. Current markers to detect and monitor exacerbations and response to treatment are based on symptoms reported by patients, clinical assessment and Early Warning Scores, which are a composite measurement of standard observations, including heart rate, blood pressure, respiratory rate and oxygen saturations. However these scores have been validated on general populations and there is concern regarding their application to COPD patients. There is currently no objective biomarke...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age 40-80 years
  • Patients hospitalized with a primary diagnosis of an acute exacerbation of COPD
  • Body mass index (BMI) ≤ 35 kg/m2
  • Cognitively and linguistically able to follow instructions given in English and provide informed consent
  • To be discharged to home following the hospitalization
  • Patient lives in the catchment area served by the Integrated Respiratory Team at Guy's and St Thomas' NHS Foundation Trust in a home environment deemed safe by the investigators to perform home assessments
  • Exclusion Criteria:
  • Previous home PAP (CPAP or NIV) therapy use within the past year, or post-discharge
  • Allergies to latex, metals or local anaesthetic agents
  • Wound or inflamed skin at parasternal location (2nd intercostal space)
  • History of skin allergies or sensitivity to cosmetics and lotions
  • Psychological and social factors that would impair compliance with study protocol and schedule
  • Any major non-COPD chronic disease or condition, such as severe heart failure (LVEF\<30%), malignancy (active treatment and palliation), end stage renal failure/dialysis, significant neuromuscular disease (e.g. NMD, MD) determined by review of medical history and / or patient reported medical history that may contribute significantly to risk of readmission, as determined by PI
  • Length of stay ≤ 24 hours
  • Planned travel away from home within the 30 day post discharge period

About Guy's And St Thomas' Nhs Foundation Trust

Guy's and St Thomas' NHS Foundation Trust is a leading healthcare organization in the United Kingdom, renowned for its commitment to delivering high-quality patient care, innovative research, and clinical excellence. As a prominent academic health science center, the Trust integrates cutting-edge research with clinical practice, facilitating the translation of scientific discoveries into improved treatment options. With a diverse portfolio of clinical trials across various medical specialties, Guy's and St Thomas' NHS Foundation Trust plays a pivotal role in advancing healthcare knowledge and enhancing patient outcomes, while maintaining the highest ethical standards in research and patient safety.

Locations

London, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Nicholas Hart, MBBSPhDFFICM

Principal Investigator

Guy's and St Thomas' NHS Foundation Trust

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials